Effects of Intensive Blood Pressure Treatment on Acute Kidney Injury Events in the Systolic Blood Pressure Intervention Trial (SPRINT)

Michael V Rocco, Kaycee M Sink, Laura C Lovato, Dawn F Wolfgram, Thomas B Wiegmann, Barry M Wall, Kausik Umanath, Frederic Rahbari-Oskoui, Anna C Porter, Roberto Pisoni, Cora E Lewis, Julia B Lewis, James P Lash, Lois A Katz, Amret T Hawfield, William E Haley, Barry I Freedman, Jamie P Dwyer, Paul E Drawz, Mirela Dobre, Alfred K Cheung, Ruth C Campbell, Udayan Bhatt, Srinivasan Beddhu, Paul L Kimmel, David M Reboussin, Glenn M Chertow, SPRINT Research Group, Michael V Rocco, Kaycee M Sink, Laura C Lovato, Dawn F Wolfgram, Thomas B Wiegmann, Barry M Wall, Kausik Umanath, Frederic Rahbari-Oskoui, Anna C Porter, Roberto Pisoni, Cora E Lewis, Julia B Lewis, James P Lash, Lois A Katz, Amret T Hawfield, William E Haley, Barry I Freedman, Jamie P Dwyer, Paul E Drawz, Mirela Dobre, Alfred K Cheung, Ruth C Campbell, Udayan Bhatt, Srinivasan Beddhu, Paul L Kimmel, David M Reboussin, Glenn M Chertow, SPRINT Research Group

Abstract

Background: Treating to a lower blood pressure (BP) may increase acute kidney injury (AKI) events.

Study design: Data for AKI resulting in or during hospitalization or emergency department visits were collected as part of the serious adverse events reporting process of the Systolic Blood Pressure Intervention Trial (SPRINT).

Setting & participants: 9,361 participants 50 years or older with 1 or more risk factors for cardiovascular disease.

Interventions: Participants were randomly assigned to a systolic BP target of <120 (intensive arm) or <140mmHg (standard arm).

Outcomes & measurements: Primary outcome was the number of adjudicated AKI events. Secondary outcomes included severity of AKI and degree of recovery of kidney function after an AKI event. Baseline creatinine concentration was defined as the most recent SPRINT outpatient creatinine value before the date of the AKI event.

Results: There were 179 participants with AKI events in the intensive arm and 109 in the standard arm (3.8% vs 2.3%; HR, 1.64; 95% CI, 1.30-2.10; P<0.001). Of 288 participants with an AKI event, 248 (86.1%) had a single AKI event during the trial. Based on modified KDIGO (Kidney Disease: Improving Global Outcomes) criteria for severity of AKI, the number of AKI events in the intensive versus standard arm by KDIGO stage was 128 (58.5%) versus 81 (62.8%) for AKI stage 1, 42 (19.2%) versus 18 (14.0%) for AKI stage 2, and 42 (19.2%) versus 25 (19.4%) for AKI stage 3 (P=0.5). For participants with sufficient data, complete or partial resolution of AKI was seen for 169 (90.4%) and 9 (4.8%) of 187 AKI events in the intensive arm and 86 (86.9%) and 4 (4.0%) of 99 AKI events in the standard arm, respectively.

Limitations: Trial results are not generalizable to patients with diabetes mellitus or without risk factors for cardiovascular disease.

Conclusions: More intensive BP lowering resulted in more frequent episodes of AKI. Most cases were mild and most participants had complete recovery of kidney function.

Trial registration: Registered at ClinicalTrials.gov with study number NCT01206062.

Keywords: Acute kidney injury (AKI); BP lowering; adjudicated AKI episode; cardiovascular disease (CKD); chronic kidney disease (CKD); elderly; hypertension; kidney function; systolic blood pressure (SBP).

Copyright © 2017 National Kidney Foundation, Inc. All rights reserved.

Figures

Figure 1
Figure 1
CONSORT diagram
Figure 2
Figure 2
Cumulative Hazard Plot for Acute Kidney Injury (CI denotes confidence interval).
Figure 3
Figure 3
Forest Plot of Acute Kidney Injury. The dashed vertical line represents the hazard ratio for the overall study population. The box sizes are proportional to the precision of the estimates (with larger boxes indicating a greater degree of precision). The subgroup of no previous chronic kidney disease (CKD) includes some participants with unknown CKD status at baseline. Black race includes Hispanic black and black as part of a multiracial identification.

Source: PubMed

3
订阅